LOOP-ENERGY
6.10.2022 12:31:37 CEST | Business Wire | Press release
Loop Energy™ (TSX: LPEN), a developer and manufacturer of hydrogen fuel cells for commercial mobility, today announces two new customers, each developing medium-duty hydrogen-electric trucks.
Opex, a Colombian systems integrator of batteries and hydrogen fuel cells, and Avia Ingeniería, a Spanish electric powertrain provider and systems integrator, are both looking to trial hydrogen-electric vehicles in 2023.
Loop Energy enters the Pilot Phase of the Customer Adoption Cycle with both companies, expanding its presence in the dynamic European market and establishing its first relationship in the emerging South American market. The news comes after Loop Energy recently upgraded its purchase order guidance for the next 18 months.
Having supplied components and infrastructure for battery-electric vehicles for more than a decade, Opex identified fuel cells as a solution for commercial vehicles in Latin America two years ago. Starting with a prototype, Opex aims to develop a logistics truck using Loop Energy's S300 (30 kW) fuel cell as a range extender. Once built, the truck is expected to be trialed by a local fleet operator to evaluate how the technology can be deployed in larger truck applications.
Avia Ingeniería plans to also apply Loop Energy's 30 kW fuel cell as a range extender in a tractor-trailer transport truck. The truck is a part of the ShineFleet project, which features various Spanish technology and engineering companies including Técnicas Reunidas. The aim of the pilot is to demonstrate the feasibility of hydrogen technology and educate fleet operators on how to scale a fleet. A logistics fleet operator is expected to integrate the truck into its service routes once it is operational in 2023.
"We've seen positive growth when it comes to using fuel cells in medium-duty electric trucks," said Loop Energy Chief Commercial Officer, George Rubin. "Our team continues to identify manufacturers and fleet operators committed to the deployment of hydrogen-electric fleets worldwide. It is great to see Opex and Avia Ingeniería setting a positive example in their respective markets."
Climate Change mitigation, regulatory pressure and energy security concerns are compelling manufacturers and fleet operators to invest in and operate hydrogen-electric trucks instead of traditional diesel combustion engine vehicles. Benefits such as extended range, lighter weight and fast refuelling are key contributors to lower total cost of ownership, making fuel cell-powered vehicles an appealing zero-emissions solution.
About Opex S.A.S.
Opex S.A.S. is a colombian based company with 10 years of experience in the market. Among its main market activities are selling and renting of products as acid lead batteries, Li-Ion batteries, and Hydrogen fuel cells. The company also provides products as forklift trucks and batteries for warehouses, including installations and maintenance of the products. During the last two years, Opex has been involved in several research projects related to clean energies and hydrogen use. We have installed the first hydrogen refueling station in the entire South America region. To learn more visit: www.opex.com.co
About Avia Ingeniería
Avia is an independent company specializing in the design, manufacture of prototypes and small series of special vehicles. The philosophy of the company as engineering is to offer its capacity to develop advanced technology projects and to be present in research projects in the fields of new energies and materials. It offers its clients solutions from the simplest execution of manufacturing drawings to the most advanced integral projects, contributing, with its knowledge, technology and computer resources. Avia brings vast experience in the fields of aeronautics, automotive, agricultural equipment and public works.
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop's products feature the company's proprietary eFlow™ technology in the fuel cell stack's bipolar plates. eFlow™ is designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.
Forward Looking Warning
This press release contains forward looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Particularly, statements regarding the Company’s or Customer’s expectations of future sales and deployment, performance, achievements, prospects or opportunities or the markets in which we operate is forward looking information, including without limitation statements regarding the trials and deployment of Opex’s and Avia’s hydrogen-electric truck, future purchase orders and projected benefits of fuel cell technology in commercial vehicles.
Forward looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward looking information. Such risks and uncertainties include, but are not limited to, the ability to scale hydrogen technology into larger applications or fleets, if vehicle OEMs and fleet operators choose not to invest and operate zero-emissions vehicles over diesel vehicles, if the benefits of fuel cell technology in commercials does not contribute to lower total cost of ownership and the factors discussed under “Risk Factors” in the Company’s Annual Information Form dated March 23, 2022. Loop disclaims any obligation to update these forward looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom